Literature DB >> 28868721

Experiences of Postcardiotomy Assist: Pneumatic Ventricular Assist Device or Venoarterial Bypass with Percutaneous Cardiopulmonary Support.

Yukihiko Orime1, Shoji Shindo1, Motomi Shiono1, Hiroaki Hata1, Shinya Yagi1, Saeki Tsukamoto1, Haruhiko Okumura1, Yukiyasu Sezai1.   

Abstract

From October 1982 to the present, 16 patients have been supported by a pneumatic ventricular assist device (VAD). Since April 1990, we have introduced a venoarterial bypass (VAB) with percutaneous cardiopulmonary support (PCPS) system. This PCPS system was used in 12 patients. The long-term survival rate of PCPS cases (41%) was much better than that of VAD cases (19%). The main cause of death in VAD cases was multiple organ failure (MOF). Although VAB was initiated more recently than VAD, the duration on support was longer in the VAD group than in the VAB group. Because of the longer support duration and the presence of many patients with MOF, coagulopathy deteriorated more readily in the VAD group than in the VAB group. In the case of postcardiotomy cardiopulmonary bypass weaning or low-output syndrome (LOS), the VAB with PCPS system should be applied first under intraaortic balloon pumping assist because of its simplicity and low cost. Thereafter, VAD should be applied in cases refractory to VAB support. © 1996 International Society for Artificial Organs.

Entities:  

Keywords:  Percutaneous cardiopulmonary support-; Postcardiotomy cardiogenic shock; Ventricular assist device-

Year:  1996        PMID: 28868721     DOI: 10.1111/j.1525-1594.1996.tb04511.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  1 in total

1.  Percutaneous cardiopulmonary support with heparin-coated circuits in postcardiotomy cardiogenic shock. Efficacy and comparison with left heart bypass.

Authors:  Y Hayashi; S Ohtake; Y Sawa; M Nishimura; H Ichikawa; H Satoh; T Yamaguchi; H Suhara; T Sakaguchi; H Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.